-
Statera BioPharma: The Ticker Formerly Known as CBLI
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases. The company began trading as CLBI, last month,…
You May Also Like
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
-
GAWK, Inc. Acquires Connexum, Will Triple Annual Revenue
PREVIOUSLY PUBLISHED TO TMC NET’S CLOUD CONTACT CENTER GAWK, Inc. is essentially an advanced data center solution with efficient cloud-based servicing and a content delivery network. This week, GAWK announced its acquisition of Connexum. This deal is set to increase annual revenues for the company at an upwards of $6 million. This acquisition will also include Connexum’s wholesale telecommunications carrier with associated product and service lines. All assets of Connexum will now belong to GAWK and will mark the third acquisition for the company in a strategy to grow cloud-based communications services. GAWK grew interested in Connexum’s position within the VoIP sector, which spurred this acquistion. This merger will ripple…
